Evaluating the Safety and Immunogenicity of EnvSeq-1 and CH505 M5 gp120 Envs Adjuvanted With GLA-SE in Healthy, HIV-Uninfected Adults
- Conditions
- HIV Infections
- Interventions
- Biological: CH505 M5Biological: PlaceboBiological: CH505TFBiological: CH505w53Biological: CH505w78Biological: GLA-SE adjuvant
- First Posted Date
- 2017-07-18
- Last Posted Date
- 2024-05-21
- Target Recruit Count
- 117
- Registration Number
- NCT03220724
- Locations
- 🇺🇸
Columbia P&S CRS, New York, New York, United States
🇺🇸New York Blood Center CRS, New York, New York, United States
🇺🇸University of Rochester Vaccines to Prevent HIV Infection CRS, Rochester, New York, United States
Treatment of Gardnerella Vaginalis Vaginal Colonization With Amoxicillin
- First Posted Date
- 2017-07-07
- Last Posted Date
- 2020-08-28
- Target Recruit Count
- 97
- Registration Number
- NCT03211156
- Locations
- 🇺🇸
University of Alabama at Birmingham School of Medicine - Infectious Disease, Birmingham, Alabama, United States
🇺🇸Guilford County Health Department - Greensboro - STD Clinic, Winston-Salem, North Carolina, United States
Evaluating the Safety and Antiviral Activity of Monoclonal Antibody VRC01 in Infants With HIV Receiving Combination Antiretroviral Therapy
- Conditions
- HIV Infections
- Interventions
- Biological: VRC01Drug: Combination Antiretroviral Therapy (cART)
- First Posted Date
- 2017-07-05
- Last Posted Date
- 2023-05-24
- Target Recruit Count
- 61
- Registration Number
- NCT03208231
- Locations
- 🇧🇼
Molepolole CRS, Molepolole, Kweneng District, Botswana
🇧🇼Gaborone CRS, Gaborone, South-East District, Botswana
🇿🇼Harare Family Care CRS, Harare, Zimbabwe
NIAID Centralized Sequencing Protocol
- Conditions
- Primary ImmunodeficiencyAtopyAutoimmunityAutoinflammation
- First Posted Date
- 2017-07-02
- Last Posted Date
- 2024-12-20
- Target Recruit Count
- 20000
- Registration Number
- NCT03206099
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
🇺🇸Children's National Health System, Washington, District of Columbia, United States
Influenza HA Ferritin Vaccine, Alone or in Prime-Boost Regimens With an Influenza DNA Vaccine in Healthy Adults
- Conditions
- Influenza
- Interventions
- Biological: VRC-FLUNPF081-00-VP (HA-F A/Sing)Biological: VRC-FLUDNA082-00-VP (DNA A/Sing)
- First Posted Date
- 2017-06-14
- Last Posted Date
- 2021-06-16
- Target Recruit Count
- 50
- Registration Number
- NCT03186781
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Safety and Immunogenicity of pDNA Vaccines Expressing HIV M Group p24^Gag Conserved Elements and/or p55^Gag, Administered With IL-12 pDNA
- Conditions
- HIV Infections
- Interventions
- Biological: p24CE1/2 pDNA VaccineBiological: p55^gag pDNA VaccineBiological: PlaceboBiological: IL-12 pDNA AdjuvantDevice: Ichor Medical Systems Intramuscular TriGrid Delivery System (TDS-IM) electroporation (EP) device
- First Posted Date
- 2017-06-09
- Last Posted Date
- 2024-02-07
- Target Recruit Count
- 56
- Registration Number
- NCT03181789
- Locations
- 🇺🇸
The Hope Clinic of the Emory Vaccine Center CRS, Decatur, Georgia, United States
🇺🇸Case Clinical Research Site, Cleveland, Ohio, United States
🇺🇸Bridge HIV CRS, San Francisco, California, United States
Trial to Evaluate the Safety, Immunogenicity and Protective Efficacy of Three or Five Administrations of GAP3KO Sporozoites
- Conditions
- Plasmodium Falciparum Infection
- Interventions
- Biological: Genetically-attenuated p52-/p36-/sap1- Plasmodium falciparum parasite (GAP3KO) strainOther: Malaria challenge
- First Posted Date
- 2017-05-30
- Last Posted Date
- 2019-09-23
- Target Recruit Count
- 26
- Registration Number
- NCT03168854
- Locations
- 🇺🇸
Kaiser Permanente Washington Health Research Institute - Vaccines and Infectious Diseases, Seattle, Washington, United States
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab
- First Posted Date
- 2017-05-30
- Last Posted Date
- 2024-12-05
- Target Recruit Count
- 35
- Registration Number
- NCT03167437
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Atopic Dermatitis (AD) and Food Allergy
- Conditions
- Non-atopic Healthy ControlsAtopic Dermatitis (AD)
- First Posted Date
- 2017-05-30
- Last Posted Date
- 2018-02-28
- Target Recruit Count
- 62
- Registration Number
- NCT03168113
- Locations
- 🇺🇸
National Jewish Health: Division of Pediatric Allergy and Clinical Immunology, Denver, Colorado, United States
Evaluating the Safety and Efficacy of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women
- Conditions
- HIV Infections
- Interventions
- Drug: Oral CABDrug: Oral TDF/FTCDrug: Placebo for oral CABDrug: Placebo for CAB LADrug: Placebo for oral TDF/FTCDrug: CAB LA
- First Posted Date
- 2017-05-23
- Last Posted Date
- 2024-09-30
- Target Recruit Count
- 3224
- Registration Number
- NCT03164564
- Locations
- 🇿🇼
St Mary's CRS, Chitungwiza, Zimbabwe
🇧🇼Gaborone CRS, Gaborone, South-East District, Botswana
🇺🇬MU-JHU Research Collaboration (MUJHU CARE LTD) CRS, Kampala, Uganda